HQ tesa Labtec Langenfeld
History

History

Founded in 1990 as an independent start-up company, Labtec GmbH soon became one of the leading development companies in the sector of transdermal patches and orally dispersible films in Europe. In 2008, the company was acquired by tesa SE. Today, tesa Labtec GmbH represents the pharmaceutical division of tesa SE.

About tesa SE


2018

This year, serialization will be a priority. At the end of 2018, the first serialized market commodity was manufactured.

We're happy to announce: All lines are now serialized; thus, our equipment meets the requirements to produce counterfeit-proof packaging.

Read more

2016

The first PAI audit – Pre-Approval Inspection required by the US Food and Drug Administration (FDA) – has been successfully completed at the development site as well as at the production sites. 

2015

Other manufacturing products are being rolled off the production line in Hamburg and continuous investments are made in terms of quality, process optimization, and infrastructure.  

2014

New R&D Pilot Production Facility

With an investment of around 900,000 Euro, tesa Labtec closes the gap between small-scale product development and large-scale production. The new location at the Langenfeld R&D Center near Dusseldorf houses high-tech production technology for pilot production under full cGMP conditions and enables the output of several thousand primary-packed patches or films per hour.

Read more

2013

Implementation of the ERP System SAPhir, an SAP system customized to meet the needs of the pharmaceutical sector.
Today, tesa Labtec supplies transdermal systems to the European and Canadian market.

2012

Further European approvals for Rapidfilm® Products

Market approvals are granted for three additional Rapidfilm products. The European authorities grant marketing authorization for Zolmitriptan 2.5 and 5 mg Rapidfilm, Olanzapine 5, 10 and 15 mg Rapidfilm, and Donepezil 5 and 10 mg Rapidfilm. These orally dispersible films are indicated for the treatment of migraine attacks, schizophrenia, and Alzheimer's disease.

Read more

2010

European Approval for Ondansetron Rapidfilm®

The European Regulatory Authorities finalize the application process for Ondansetron 4 and 8 mg Rapidfilm® and issue the market approval. It is the world's first prescription drug ever approved in an oral dissolvable film form.

Read more

2009

Opening of a new production site in Hamburg

With the opening of a high-tech production site, the company now offers all order-related services for transdermal patches and oral films. The manufacturing facility uses the latest coating and processing technologies in a clean room environment.

Read more

2008

Labtec is taken over by tesa SE

tesa SE acquires the "Labtec Gesellschaft für Technologische Forschung und Entwicklung mbH" (Labtec Corporation for Technological Research and Development mbH) as part of its strategy to build up further technologically sophisticated business areas. The competences of tesa and Labtec complement each other optimally, particularly with regard to the development of innovative coated therapy systems that combine polymer chemistry and medical expertise.

 

Read more

2005

Launch of a pain suppression patch

The pain suppression patch developed by Labtec has conquered the European market. In Germany, by far the largest European market for painkiller patches, it has developed into the best-selling product. The product is distributed by a number of well-known companies, such as ratiopharm/Teva.

Read more

1990

Foundation of "Labtec Gesellschaft zur technologischen Forschung und Entwicklung mbH"
(Labtec Corporation for Technological Research and Development mbH)

Labtec was founded by Dr. Günter Cordes, a former board member of Schwarz Pharma AG and a pioneer in transdermal drug delivery.

Read more